Skip to content
2000
Volume 22, Issue 16
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612822666160304151011
2016-05-01
2025-06-01
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612822666160304151011
Loading

  • Article Type:
    Research Article
Keyword(s): Cancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRs
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test